Ceftazidime-Resistant Klebsiella pneumoniae Bloodstream Infection in Children with
Febrile Neutropenia
Hany Ariffin, MBBS, MPaed; Parasakthi Navaratnam, MBBS; Mahfuzah Mohamed,
MBBS; Anusha Arasu, MBBS; Wan Ariffin Abdullah, MBBS; Chan Lee Lee, MBBS; and
Lin Hai Peng, MBBS
Int J Infect Dis 1999; 4:21-25
Objectives: To evaluate prevalence of ceftazidime-resistant Klebsiella pneumoniae (CRKP)
in the pediatric oncology unit of University Hospital, Kuala, Lumpur, and to identify
differences between febrile neutropenic pediatric patients with CRKP and
ceftazidime-sensitive K. pneumoniae (CSKP) bacteremia. Materials and Methods: Febrile
neutropenic patients treated between January 1996 and December 1997 at the pediatric
oncology unit of University Hospital, Kuala Lumpur, were prospectively studied. Empirical
antibiotic therapy consisted of ceftazidime and amikacin. Those who developed K.
pneumoniae bacteremia were identified, and clinical features analyzed.
Ceftazidime-resistance was documented via disk-diffusion testing. Production of
extended-spectrum beta-lactamase (ESBL) was inferred on the basis of synergy between
ceftazidime and amoxicillin-clavulanic acid. The different features between the two groups
and variables associated with the development of CRKP bacteremia were analyzed using
chi-square and t-tests and calculation of odds ratios. A multivariate analysis was used to
identify independent factors for CRKP development. Results: Ceftazidime-resistance was
seen in 51.6% of all K. pneumoniae isolates, and all these isolates were inferred to be ESBL
producers. All isolates were sensitive to imipenem. Susceptibility to gentamicin was 90.5%.
The mean continuous hospital stay prior to the detection of bacteremia was 13.7 days
overall, but significantly longer in the CRKP group (21.9 d) compared to the CSKP group
(4.3 d) (P = 0.003). Children with CRKP were more likely to have received antibiotics in
the 2 weeks prior to detection of bacteremia (87.5% of cases) than the CSKP group (20.0%
of cases) (P = 0.0008). Sepsis-related mortality was higher in those with CRKP (50.0%)
than in the CSKP group (13.3%) (P = 0.02). Patients who did not receive CRKP-directed
antibiotics within 48 hours of admission were more likely to have a fatal outcome than those
who did (P = 0.009). Logistic regression analysis identified use of third-generation
cephalosporins 2 weeks prior to presentation and a hospital stay of 2 weeks or more as
independent risk factors for development of CRKP. Conclusions: More than half of total K.
pneumoniae isolated from blood cultures in the unit were ceftazidime-resistant. Children
with febrile neutropenia with prolonged hospital stay and recent prior antibiotic exposure
are at high risk of developing CRKP bacteremia. Mortality was significantly higher in this
group. Early commencement of appropriate antibiotics (e.g., imipenem with or without
gentamicin), according to susceptibility study results, may be beneficial in such
circumstances.
KEYWORDS:
ceftazidime-resistance, extended-spectrum beta-lactamase, Klebsiella pneumoniae
Back to Table of Contents
The International Journal of Infectious Diseases is owned by
the International Society for Infectious Diseases.
The Journal is published quarterly for the ISID by B.C. Decker Inc.
|